Elvitegravir: a once-daily inhibitor of HIV-1 integrase (Q37982825)

26 August 2017

title

Elvitegravir: a once-daily inhibitor of HIV-1 integrase (English)

1 reference

26 August 2017

1 reference

ChEBI release 2020-05-28

Todd Wills

1

1 reference

26 August 2017

Vivian Vega

series ordinal

2

1 reference

26 August 2017

language of work or name

English

0 references

publication date

10 February 2012

1 reference

Expert Opinion on Investigational Drugs

26 August 2017

published in

1 reference

26 August 2017

volume

21

1 reference

26 August 2017

issue

3

1 reference

26 August 2017

page(s)

395-401

1 reference

Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.658914

HIV-1 integrase inhibitors: an emerging clinical reality

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.658914

Emerging role of integrase inhibitors in the management of treatment-experienced patients with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.658914

HIV-1 integrase inhibitor resistance and its clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.658914

Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.658914

Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.658914

Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.658914

Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.658914

Elvitegravir: a new HIV integrase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.658914

Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.658914

Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.658914

Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.658914

Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.658914

Human immunodeficiency virus integrase inhibitors efficiently suppress feline immunodeficiency virus replication in vitro and provide a rationale to redesign antiretroviral treatment for feline AIDS

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.658914

Structural and Functional Analyses of the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir (S/GSK1349572)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.658914

Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.658914

Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.658914

10.1517/13543784.2012.658914

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference